Faricimab, the first bispecific anti-VEGF agent, shows promise in managing treatment-resistant neovascular Age-Related Macular Degeneration (AMD). This retrospective 12-month study analyzed 191 eyes from 156 patients at Salisbury District Hospital, UK, focusing on anatomical and functional outcomes.
Note: Explore the full-length article at the link provided below.
Patients experienced significant central subfield thickness (CST) reduction, while Best-Corrected Visual Acuity (BCVA) remained stable. Faricimab allowed extended injection intervals, reducing treatment burdens for patients and caregivers.
These findings highlight Faricimab's potential as a viable alternative for persistent AMD cases. Long-term studies are necessary to assess the durability of these results.
Read the full study for deeper insights!
Content Details:-
Corresponding author: : Evans W, Department of Ophthalmology, Salisbury District Hospital, Odstock Road, Salisbury, UK.
Full Length Article: Real-World Efficacy of Faricimab in Treatment ResistantNeovascular Age-Related Macular Degeneration: A 12Month Cohort Study
Journal: Austin Ophthalmology
Disclaimer: This content is not owned or created by us. It has been sourced from the respective site, Austin Publishing Group, and is intended purely for study and educational purposes. All rights belong to the original authors and publishers.
.png)
No comments:
Post a Comment